| 1/12/2022 |
Edward Jones Upgrades CVS Health (NYSE:CVS) to Buy - Mayfield Recorder |
Mayfield Recorder |
... on Wednesday, December 1st. Deutsche Bank Aktiengesellschaft upped their price target on CVS Health from $101.00 to $107.00 and gave the stock a “buy” rating in a report on Friday, November 5th. The Goldman Sachs Group began coverage on CVS Health in a report on Tuesday, December 14th. They issued a “buy” rating and a $121.00 price target on the stock. Finally, Credit Suisse Group upped their price ... |
| 1/12/2022 |
Sanford C. Bernstein Raises CVS Health (NYSE:CVS) Price Target to $116.00 |
dispatchtribunal.com |
... target price on CVS Health from $98.00 to $111.00 and gave the stock a buy rating in a research report on Thursday, November 4th. They noted that the move was a valuation call. The Goldman Sachs Group started coverage on CVS Health in a report on Tuesday, December 14th. They set a buy rating and a $121.00 price objective on the stock. Finally, Raymond James raised their target price on ... |
| 1/12/2022 |
GoodRx (NASDAQ:GDRX) Stock Rating Upgraded by Zacks Investment Research |
dispatchtribunal.com |
... Zacks.com reports.According to Zacks, “GoodRx Holdings Inc. provides consumer-focused digital healthcare platform. GoodRx Holdings Inc. is based in Santa Monica, California. “Several other brokerages have also weighed in on GDRX. The Goldman Sachs Group initiated coverage on shares of GoodRx in a research report on Friday. They set a “buy” rating and a $43.00 target price on the stock. Jefferies Financial Group initiated coverage on shares ... |
| 1/12/2022 |
Investment Analysts’ Recent Ratings Updates for Pfizer (PFE) - American Banking News |
American Banking News |
A number of research firms have changed their ratings and price targets for Pfizer (NYSE: PFE):1/11/2022 – Pfizer was given a new $54.00 price target on by analysts at Barclays PLC. 1/10/2022 – Pfizer was given a new $51.00 price target on by analysts at The Goldman Sachs Group, Inc.. 1/7/2022 – Pfizer had its price target raised by analysts at Wells Fargo & Company from $60.00 to $65.00. They ... |
| 1/12/2022 |
Investment Analysts’ Recent Ratings Updates for Pfizer (PFE) |
baseballnewssource.com |
A number of research firms have changed their ratings and price targets for Pfizer (NYSE: PFE):- 1/11/2022 – Pfizer was given a new $54.00 price target on by analysts at Barclays PLC.- 1/10/2022 – Pfizer was given a new $51.00 price target on by analysts at The Goldman Sachs Group, Inc..- 1/7/2022 – Pfizer had its price target raised by analysts at Wells Fargo & Company from $60.00 to $65.00. They ... |
| 1/12/2022 |
Investment Analysts’ Recent Ratings Updates for Pfizer (PFE) |
com-unik.info |
A number of research firms have changed their ratings and price targets for Pfizer (NYSE: PFE):- 1/11/2022 – Pfizer was given a new $54.00 price target on by analysts at Barclays PLC.- 1/10/2022 – Pfizer was given a new $51.00 price target on by analysts at The Goldman Sachs Group, Inc..- 1/7/2022 – Pfizer had its price target raised by analysts at Wells Fargo & Company from $60.00 to $65.00. They ... |
| 1/12/2022 |
Meeder Asset Management Inc. Buys 3,144 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) |
Ticker Report |
... number of other hedge funds also recently bought and sold shares of the stock. Artisan Partners Limited Partnership bought a new stake in shares of Myriad Genetics during the 2nd quarter valued at $34,054,000. Goldman Sachs Group Inc. raised its position in shares of Myriad Genetics by 65.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 2,214,690 shares of the company’s stock valued at $67,725,000 after acquiring ... |
| 1/12/2022 |
Nobilis Health (NYSEAMERICAN:HLTH) Trading Up 3.1% - Slater Sentinel |
slatersentinel.com |
... Wednesday. Morgan Stanley started coverage on shares of Nobilis Health in a research report on Tuesday, October 19th. They set an “equal weight” rating and a $12.00 target price on the stock. The Goldman Sachs Group started coverage on shares of Nobilis Health in a research report on Tuesday, October 19th. They set a “buy” rating and a $19.00 target price on the stock. BTIG Research started coverage ... |
| 1/12/2022 |
BioNTech (NASDAQ:BNTX) Raised to “Strong-Buy” at Zacks Investment Research |
com-unik.info |
... set a $359.00 target price on BioNTech in a research note on Tuesday, October 5th. Jefferies Financial Group set a $230.00 target price on BioNTech in a research note on Wednesday, December 8th. The Goldman Sachs Group set a $433.00 target price on BioNTech in a research note on Wednesday, September 29th. Finally, Deutsche Bank Aktiengesellschaft set a $225.00 price target on BioNTech in a research report on Thursday, December ... |
| 1/12/2022 |
Mizuho Americas Hires Graig C. Suvannavejh, PhD, as Senior Biopharmaceuticals and Biotechnology Analyst | 2022-01-12 | Press Releases | Stockhouse |
stockhouse.com |
... both bulge bracket and healthcare-dedicated boutique investment banks and corporate experience with operating roles in business development and strategy at top-tier global biopharmaceutical companies, including AbbVie and Biogen. He joins Mizuho from Goldman Sachs , where he successfully built out and led the European biotechnology research franchise there, and was a key player in the firm&CloseCurlyQuote: ;s US biopharmaceuticals research efforts.“Graig has a wealth of sell-side ... |
| 1/12/2022 |
US and UK buyout barons join forces in battle for Boots: Bain teams up with CVC in the £7bn takeover battle after teaming up to make a bid. |
MSN |
... as frontrunners in the £7billion takeover battle, after teaming up to make a bid.Boots, which has 2,200 stores and employs 51,000 people, has been attracting attention since its owner Walgreens Alliance Boots hired Goldman Sachs last month to mastermind a sale.© Provided by This Is Money American buyout barons at Bain Capital and their counterparts at British giant CVC Capital Partners have emerged as frontrunners in the £7bn takeover ... |
| 1/11/2022 |
CVS Health (NYSE:CVS) Raised to “Buy” at Edward Jones - American Banking News |
American Banking News |
... stock. Seaport Research Partners assumed coverage on shares of CVS Health in a research report on Wednesday, December 1st. They set a “buy” rating and a $110.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of CVS Health in a report on Tuesday, December 14th. They issued a “buy” rating and a $121.00 target price for the company. Citigroup increased shares of CVS ... |
| 1/11/2022 |
Edward Jones Initiates Coverage on UnitedHealth Group (NYSE:UNH) - American Banking News |
American Banking News |
... Research raised shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $477.00 price target for the company in a research report on Wednesday, October 27th. The Goldman Sachs Group initiated coverage on shares of UnitedHealth Group in a research report on Tuesday, December 14th. They set a “buy” rating and a $535.00 price target for the company. Finally, Truist upped their ... |
| 1/11/2022 |
Centene (NYSE:CNC) PT Raised to $108.00 |
dispatchtribunal.com |
... of several other research reports. Morgan Stanley increased their price target on Centene from $86.00 to $109.00 and gave the company an “overweight” rating in a research note on Friday, December 17th. The Goldman Sachs Group started coverage on Centene in a research report on Tuesday, December 14th. They set a “neutral” rating and a $83.00 target price on the stock. TheStreet upgraded Centene from a “c+” ... |
| 1/11/2022 |
UnitedHealth Group (NYSE:UNH) Now Covered by Analysts at Edward Jones - Mayfield Recorder |
Mayfield Recorder |
... target for the company. Royal Bank of Canada increased their price target on UnitedHealth Group from $476.00 to $512.00 and gave the stock an outperform rating in a report on Wednesday, December 1st. The Goldman Sachs Group began coverage on UnitedHealth Group in a report on Tuesday, December 14th. They set a buy rating and a $535.00 price target for the company. Mizuho increased their price target on UnitedHealth Group ... |
| 1/11/2022 |
Frist named CEO at naviHealth |
McKnight's Long Term Care News |
... last year. Richards is now serving in a senior advisory role at Optum, which acquired naviHealth in 2020.Frist joined naviHealth in 2012. He was previously an investment professional for The Carlyle Group and Goldman Sachs & Co. He also worked for Chinaco Healthcare Corporation, an international hospital operator.Frist earned an MBA from Harvard Business School and an undergraduate degree in history from Princeton University ... |
| 1/11/2022 |
Oscar Health (NYSE:OSCR) Sets New 1-Year Low Following Analyst Downgrade - Mayfield Recorder |
Mayfield Recorder |
... traded as low as $6.70 and last traded at $6.74, with a volume of 7211 shares traded. The stock had previously closed at $6.89.Several other equities analysts also recently commented on OSCR. The Goldman Sachs Group started coverage on Oscar Health in a report on Tuesday, December 14th. They set a “sell” rating and a $6.50 price target on the stock. Morgan Stanley lowered their price target on ... |
| 1/11/2022 |
Truist Securiti Weighs in on Gilead Sciences, Inc.'s Q4 2021 Earnings (NASDAQ:GILD) |
dispatchtribunal.com |
... Tuesday, December 14th. Piper Sandler began coverage on shares of Gilead Sciences in a report on Friday, November 19th. They set a “neutral” rating and a $77.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of Gilead Sciences in a report on Monday, December 6th. They set a “neutral” rating and a $80.00 price objective on the stock. Finally, Morgan Stanley downgraded shares ... |
| 1/11/2022 |
Humana (NYSE:HUM) Price Target Cut to $410.00 by Analysts at Morgan Stanley - Ticker Report |
Ticker Report |
... Company upgraded shares of Humana from an equal weight rating to an overweight rating and boosted their price objective for the company from $492.00 to $529.00 in a report on Thursday, January 6th. The Goldman Sachs Group initiated coverage on shares of Humana in a research note on Tuesday, December 14th. They set a neutral rating and a $472.00 price target on the stock. Truist Securities boosted their price objective ... |
| 1/11/2022 |
5 Dividend Stocks For January 2022 |
inyoregister.com |
... given the uncertainty around the current direction of markets. On one hand, you have the Federal Reserve’s fast-approaching plans to raise interest rates. According to big banks like JPMorgan ( NYSE: JPM ) and Goldman Sachs ( NYSE: GS ), we could see upwards of four hikes in 2022. On the other hand, rising coronavirus concerns continue to weigh in on the overall reopening trade. In theory, all this could deter investors ... |